肿瘤细胞治疗研究
英文原题：Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma.
Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma.
随着基因组工程技术的进步，基于嵌合抗原受体（CARs）的免疫疗法已成为肿瘤的一种新兴治疗策略。
随着基因组工程技术的发展，基于嵌合抗原受体（CARs）的免疫治疗已成为一种新兴的肿瘤治疗策略。尽管最初是为肿瘤免疫治疗中的T细胞而设计，CARs已被用于改造自然杀伤（NK）细胞的功能，以对抗包括肝细胞癌（HCC）在内的多种肿瘤。CAR-NK细胞有潜力充分杀伤表达肿瘤抗原的HCC细胞，且不依赖于主要组织相容性复合体的匹配或预先致敏。在这篇综述中，我们总结了针对HCC的CAR-NK细胞基因工程的最新进展，并讨论了CAR-NK细胞作为一种革命性细胞免疫疗法治疗HCC的当前挑战和前景。
With the advance of genome engineering technology, chimeric antigen receptors (CARs)-based immunotherapy has become an emerging therapeutic strategy for tumors. Although initially designed for T cells in tumor immunotherapy, CARs have been exploited to modify the function of natural killer (NK) cells against a variety of tumors, including hepatocellular carcinoma (HCC). CAR-NK cells have the potential to sufficiently kill tumor antigen-expressing HCC cells, independent of major histocompatibility complex matching or prior priming. In this review, we summarize the recent advances in genetic engineering of CAR-NK cells against HCC and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against HCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
